Venetoclax with azacitidine for untreated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of venetoclax and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) who cannot have or choose not to have intensive chemotherapy. The goal is to see if adding a drug called cobicistat helps the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of AML (not a subtype called promyelocytic leukemia) and may have been treated for a prior blood disorder with certain drugs.
- You are 18 or older and not a candidate for or choose not to receive intensive chemotherapy.
- You are in generally good physical condition, able to carry out daily activities with minor help (WHO performance score 0, 1, or 2).
- Your kidneys and liver are working well enough, as shown by blood tests (creatinine clearance at least 30 mL/min, bilirubin and ALT within limits).
- If you are a man who can father a child, you agree to use contraception and not donate sperm during and 90 days after treatment. If you are a woman who can get pregnant, you agree to use contraception during and 180 days after treatment.
- You have not had prior treatment for AML or MDS (except for certain drugs like hydroxyurea for high white blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.